Literature DB >> 7528733

Reconstituted high-density lipoprotein neutralizes gram-negative bacterial lipopolysaccharides in human whole blood.

T S Parker1, D M Levine, J C Chang, J Laxer, C C Coffin, A L Rubin.   

Abstract

We have tested hypotheses relating lipoprotein structure to function as measured by the relative ability to neutralize endotoxin by comparing natural human lipoproteins, a chemically defined form of reconstituted high-density lipoprotein (R-HDL), and a lipid emulsion (Intralipid). The human whole-blood system was used as an in vitro model of lipopolysaccharide (LPS) binding protein and CD14-dependent activation of cytokine production. When lipoproteins were compared on the basis of protein content, R-HDL was most effective in reducing tumor necrosis factor alpha (TNF-alpha) production followed in order by very low density lipoprotein, low-density lipoprotein, Intralipid, and natural HDL. However, when these particles were compared by protein, phospholipid, cholesterol, or triglyceride content by stepwise linear regression analysis, only phospholipid was correlated to effectiveness (r2 = 0.873; P < 0.0001). Anti-CD14 monoclonal antibodies MY4 and 3C10 inhibited LPS binding protein and CD14-dependent activation of TNF-alpha production by LPS at LPS concentrations up to approximately 1.0 ng/ml. R-HDL (2 mg of protein per ml) blocked TNF-alpha production by LPS from both smooth- and rough-type gram-negative bacteria at concentrations up to 100 ng of LPS per ml but had little effect on heat-killed gram-positive Staphylococcus aureus and no effect on other LPS-independent stimuli tested. These results support our hypothesis that LPS is neutralized by binding to phospholipid on the surface of R-HDL and demonstrate that R-HDL is a potent inhibitor of the induction of TNF-alpha by LPS from both rough- and smooth-form gram-negative bacteria in whole human blood.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7528733      PMCID: PMC172985          DOI: 10.1128/iai.63.1.253-258.1995

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  44 in total

1.  Single vertical spin density gradient ultracentrifugation.

Authors:  B H Chung; J P Segrest; M J Ray; J D Brunzell; J E Hokanson; R M Krauss; K Beaudrie; J T Cone
Journal:  Methods Enzymol       Date:  1986       Impact factor: 1.600

2.  Enzymatic methods for quantification of lipoprotein lipids.

Authors:  G R Warnick
Journal:  Methods Enzymol       Date:  1986       Impact factor: 1.600

3.  The reassociation of lipopolysaccharide, phospholipid, and transferase enzymes of the bacterial cell envelope. Isolation of binary and ternary complexes.

Authors:  M M Weiser; L Rothfield
Journal:  J Biol Chem       Date:  1968-03-25       Impact factor: 5.157

4.  Inhibition of endotoxin-induced activation of human monocytes by human lipoproteins.

Authors:  W A Flegel; A Wölpl; D N Männel; H Northoff
Journal:  Infect Immun       Date:  1989-07       Impact factor: 3.441

5.  Identification of a lipid A binding site in the acute phase reactant lipopolysaccharide binding protein.

Authors:  P S Tobias; K Soldau; R J Ulevitch
Journal:  J Biol Chem       Date:  1989-06-25       Impact factor: 5.157

6.  Composition and structure of lipopolysaccharide-human plasma low density lipoprotein complex. Analytical ultracentrifugation, 31P-NMR, ESR and fluorescence spectroscopy studies.

Authors:  A V Victorov; N V Medvedeva; E M Gladkaya; A D Morozkin; E A Podrez; V A Kosykh; V A Yurkiv
Journal:  Biochim Biophys Acta       Date:  1989-08-21

7.  A rapid method for the synthesis of protein-lipid complexes using adsorption chromatography.

Authors:  E A Bonomo; J B Swaney
Journal:  J Lipid Res       Date:  1988-03       Impact factor: 5.922

8.  A family of lipopolysaccharide binding proteins involved in responses to gram-negative sepsis.

Authors:  P S Tobias; J C Mathison; R J Ulevitch
Journal:  J Biol Chem       Date:  1988-09-25       Impact factor: 5.157

9.  Behavior of human apolipoprotein A-I: phospholipid and apoHDL:phospholipid complexes in vitro and after injection into rabbits.

Authors:  J Koizumi; M Kano; K Okabayashi; A Jadhav; G R Thompson
Journal:  J Lipid Res       Date:  1988-11       Impact factor: 5.922

10.  Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits.

Authors:  J C Mathison; E Wolfson; R J Ulevitch
Journal:  J Clin Invest       Date:  1988-06       Impact factor: 14.808

View more
  39 in total

1.  High-density lipoprotein suppresses the type I interferon response, a family of potent antiviral immunoregulators, in macrophages challenged with lipopolysaccharide.

Authors:  Masashi Suzuki; David K Pritchard; Lev Becker; Andrew N Hoofnagle; Natsuko Tanimura; Theo K Bammler; Richard P Beyer; Roger Bumgarner; Tomas Vaisar; Maria C de Beer; Frederick C de Beer; Kensuke Miyake; John F Oram; Jay W Heinecke
Journal:  Circulation       Date:  2010-10-25       Impact factor: 29.690

2.  Low density lipoprotein inactivates Vibrio vulnificus cytolysin through the oligomerization of toxin monomer.

Authors:  Kwang-Hyun Park; Haet-Bit Yang; Hyung-Gue Kim; Young-Rae Lee; Hyoun Hur; Jong-Soo Kim; Bon-Sun Koo; Myung-Kwan Han; Jong-Hyun Kim; Young-Ju Jeong; Jong-Suk Kim
Journal:  Med Microbiol Immunol       Date:  2004-11-20       Impact factor: 3.402

3.  High density lipoprotein protects against polymicrobe-induced sepsis in mice.

Authors:  Ling Guo; Junting Ai; Zhong Zheng; Deborah A Howatt; Alan Daugherty; Bin Huang; Xiang-An Li
Journal:  J Biol Chem       Date:  2013-05-08       Impact factor: 5.157

Review 4.  Proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond.

Authors:  Amy S Shah; Lirong Tan; Jason Lu Long; W Sean Davidson
Journal:  J Lipid Res       Date:  2013-02-24       Impact factor: 5.922

5.  Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia.

Authors:  D Pajkrt; J E Doran; F Koster; P G Lerch; B Arnet; T van der Poll; J W ten Cate; S J van Deventer
Journal:  J Exp Med       Date:  1996-11-01       Impact factor: 14.307

6.  Endotoxin and cytokines decrease serum levels and extra hepatic protein and mRNA levels of cholesteryl ester transfer protein in syrian hamsters.

Authors:  I Hardardóttir; A H Moser; J Fuller; C Fielding; K Feingold; C Grünfeld
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

Review 7.  The structure and function of serum opacity factor: a unique streptococcal virulence determinant that targets high-density lipoproteins.

Authors:  Harry S Courtney; Henry J Pownall
Journal:  J Biomed Biotechnol       Date:  2010-07-08

Review 8.  NKT cells in sepsis.

Authors:  Briana Leung; Hobart W Harris
Journal:  Clin Dev Immunol       Date:  2010-10-04

9.  Activation of human endothelial cells by viable or heat-killed gram-negative bacteria requires soluble CD14.

Authors:  R F Noel; T T Sato; C Mendez; M C Johnson; T H Pohlman
Journal:  Infect Immun       Date:  1995-10       Impact factor: 3.441

Review 10.  Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock.

Authors:  Edwin S Van Amersfoort; Theo J C Van Berkel; Johan Kuiper
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.